BioNxt Solutions Inc. (CVE:BNXT) | Finanzwire

Basculer en Français

10815	Companies
234312	Keywords
163099	Articles
125292	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 08/04/2026 at 09:10, 5 days 23 hours ago

BioNxt Solutions Updates on Sublingual Drug Delivery Progress

Intellectual Property Pharmaceutical Innovation Sublingual Drug Delivery Cladribine Development Everolimus And Semaglutide
PRESS RELEASE

published on 08/04/2026 at 09:05, 6 days ago

BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
BioNxt Solutions Inc. provides update on proprietary drug delivery pipeline focusing on Cladribine for MS, autoimmune diseases, Everolimus, Semaglutide. Strengthening IP portfolio

BioNxt Solutions Inc. Intellectual Property Autoimmune Diseases Cladribine Drug Delivery Pipeline
BRIEF

published on 08/01/2026 at 00:30, 9 days 8 hours ago

BioNxt Solutions Issues New Stock Options

Stock Options Canadian Securities Exchange Vesting BioNxt Solutions Option Plan
PRESS RELEASE

published on 08/01/2026 at 00:25, 9 days 8 hours ago

BioNxt Solutions Announces Option Grants
BioNxt Solutions Inc. announces stock options grants under Option Plan to insiders, consultants, and employees. Focus on drug delivery innovations and cancer treatment platforms

Stock Options Cancer Treatment Innovations BioNxt Solutions Inc. Drug Delivery
BRIEF

published on 07/06/2026 at 09:10, 1 month 3 days ago

BioNxt Progresses with Sublingual Semaglutide ODF Development

Drug Delivery Pharmaceutical Development BioNxt Solutions Sublingual ODF GLP-1 Therapeutics
PRESS RELEASE

published on 07/06/2026 at 09:05, 1 month 4 days ago

BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
BioNxt Solutions Inc. announces progress in Semaglutide oral dissolvable film program for GLP-1 therapies, expanding into a rapidly growing pharmaceutical market

BioNxt Solutions Inc. Pharmaceutical Market Oral Dissolvable Film GLP-1 Therapies Semaglutide
BRIEF

published on 06/23/2026 at 23:25, 1 month 16 days ago

BioNxt Solutions Completes $2M Non-brokered Private Placement

Private Placement Securities Warrants Investments BioNxt Solutions
PRESS RELEASE

published on 06/23/2026 at 23:20, 1 month 16 days ago

BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
BioNxt Solutions Inc. closes non-brokered private placement of units, plans to use proceeds for research and operations in Europe. Company updates on unsecured convertible debentures extension

Private Placement BioNxt Solutions Inc. Debt Extension European Research Bioscience Innovator
BRIEF

published on 06/15/2026 at 09:50, 1 month 24 days ago

BioNxt Advances Commercialization for Patented Multiple Sclerosis Treatment

Business Development Multiple Sclerosis Cladribine BioNxt Solutions BNT23001
PRESS RELEASE

published on 06/15/2026 at 09:45, 1 month 24 days ago

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
BioNxt Solutions Inc. partners with a BD&L advisor to commercialize BNT23001, a sublingual Cladribine ODF for MS. Preparing for a human bioavailability study

BioNxt Solutions Inc. Commercialization BNT23001 Bioavailability Study BD&L Advisor

Accesswire

Published on 08/10/2026 at 08:00, 1 hour 8 minutes ago

Galantas Gold Expands Indiana Drill Program to 12,500 Metres
Published on 08/10/2026 at 08:00, 1 hour 8 minutes ago

Results of AGM and Management Update Presentation
Published on 08/08/2026 at 00:00, 2 days 9 hours ago

Boron One Announces Change of Auditor
Published on 08/07/2026 at 23:15, 2 days 9 hours ago

Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days 10 hours ago

Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing

View all ACCESSWIRE

EQS Group

Published on 08/10/2026 at 08:30, 38 minutes ago

Suspension - Ashington Innovation PLC
Published on 08/10/2026 at 08:30, 38 minutes ago

DATAGROUP Wins Contract for Comprehensive Workplace Services and Device Lifecycle Management at Investitionsbank Berlin
Published on 08/10/2026 at 08:00, 1 hour 8 minutes ago

Partners Group sees strong growth at US HVAC portfolio companies as extreme weather increases demand for cooling
Published on 08/10/2026 at 08:00, 1 hour 8 minutes ago

Eleving Group 6M results ended on June 30, 2026
Published on 08/10/2026 at 08:00, 1 hour 8 minutes ago

Transaction in Own Shares

Les Echos

Published on 08/10/2026 at 07:00, 2 hours 8 minutes ago

BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Published on 08/07/2026 at 18:54, 2 days 14 hours ago

Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 2 days 14 hours ago

Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 17:49, 2 days 15 hours ago

Crédit Agricole CIB announced the publication of the Amendment of its 2025 Universal Registration Document
Published on 08/07/2026 at 08:30, 3 days ago

Disclosure of shares outstanding and voting rights - 07.08.2026

View all LES ECHOS COMFI WIRE